Chief Executive

Biotangents was founded in 2015 by Dr Andy Hall-Ponselè and Lina Gasiūnaitė. Having supported the creation of the company and the founding scientists from the beginning, Alan Hale joined as CEO in 2016. Alan was always clear in his intention to step down when the business approached the commercialisation phase and hence this has created the need for a new CEO with the appropriate skillset to lead the company in its next phase. Alan will offer operational support to the incoming CEO and will remain a core member of the board and a substantial shareholder.

The business is focussed on improving animal welfare and driving efficient husbandry practices by developing the next generation of molecular diagnostics for animal health. We have a proprietary technology called Moduleic Sensing™ that allows simpler protocols for in-clinic and on-farm diagnostic testing for infectious diseases. We use innovative bioinformatics and machine learning approaches to optimise development. The result is a rapid and cost-effective high throughput diagnostic test design, at scale, that solves real world animal health problems.

We have excited the marketplace with top global companies expressing interest. The patent pending Moduleic Sensing™ technology and advanced artificial intelligence set Biotangents apart from traditional diagnostic companies.

To date Biotangents has raised over £2m in equity investment and currently occupies 3,000 sq. ft office and laboratory facilities with a small manufacturing unit to support product development and provide room for future expansion as the product portfolio increases. Relationships have been cultivated with expert partners including the Roslin Institute and Biobest Laboratories and interest developed from over 20 animal health companies.

Biotangents now requires a CEO to accelerate growth and commercialise its products within the animal diagnostics markets.  The CEO will lead the company during the rapid sales growth phase and prepare the business for exit in 2-3 years from now.  They will provide credible and creative leadership to ensure long-term success, product sustainability and enhance organisational capability to deliver both revenue and product development programmes which meet the needs of customers, the diagnostic sector and drive shareholder value.

With demonstrable credibility and experience of leading business in Ag-tech, Animal diagnostics and global agribusiness, the CEO will have extensive technical and commercial experience of operating in markets such as Animal Pharma, animal diagnostics and the supply chain across veterinarian supplies.  The successful candidate will have a track record of achievement at a senior professional level within both large international companies and SMEs and will be a well-recognised and respected figure with an extensive network.  They will have a track record in successful fund-raising from both private and public sources and experience of in/out licensing and technology transfer.

A full candidate brochure is available on request.

To apply, please send your CV with covering letter to Ailsa Sutherland at FWB Park Brown at ailsa@fwbparkbrown.com.